Neuroprotection and Mechanism of Gas-miR36-5p from Gastrodia elata in an Alzheimer's Disease Model by Regulating Glycogen Synthase Kinase-3β.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Alzheimer Disease*/drug therapy ; Alzheimer Disease*/genetics ; Alzheimer Disease*/metabolism ; Animal Diseases* ; Gastrodia*/genetics ; MicroRNAs*/metabolism ; MicroRNAs*/pharmacology ; Neurodegenerative Diseases* ; Neuroprotective Agents*/pharmacology ; Neuroprotective Agents*/therapeutic use; Animals ; Mice ; Glycogen Synthase Kinase 3 beta/drug effects ; Glycogen Synthase Kinase 3 beta/genetics ; Glycogen Synthase Kinase 3 beta/metabolism ; Neuroprotection ; Phosphorylation ; tau Proteins/metabolism

Alzheimer's disease (AD) is currently the most common neurodegenerative disease. Glycogen synthase kinase 3β (GSK-3β) is a pivotal factor in AD pathogenesis. Recent research has demonstrated that plant miRNAs exert cross-kingdom regulation on the target genes in animals. Gastrodia elata ( G. elata ) is a valuable traditional Chinese medicine that has significant pharmacological activity against diseases of the central nervous system (CNS). Our previous studies have indicated that G. elata -specific miRNA plays a cross-kingdom regulatory role for the NF- κ B signaling pathway in mice. In this study, further bioinformatics analysis suggested that Gas-miR36-5p targets GSK-3β. Through western blot, RT-qPCR, and assessments of T-AOC, SOD, and MDA levels, Gas-miR36-5p demonstrated its neuroprotective effects in an AD cell model. Furthermore, Gas-miR36-5p was detected in the murine brain tissues. The results of the Morris water maze test and western blot analysis provided positive evidence for reversing the learning deficits and hyperphosphorylation of Tau in AD mice, elucidating significant neuroprotective effects in an AD model following G. elata RNA administration. Our research emphasizes Gas-miR36-5p as a novel G. elata -specific miRNA with neuroprotective properties in Alzheimer's disease by targeting GSK-3β. Consequently, our findings provide valuable insights into the cross-kingdom regulatory mechanisms underlying G. elata -specific miRNA, presenting a novel perspective for the treatment of Alzheimer's disease.

Curr Opin Struct Biol. 2005 Jun;15(3):331-41. (PMID: 15925505)
Philos Trans R Soc Lond B Biol Sci. 2016 Aug 5;371(1700):. (PMID: 27377723)
Ageing Res Rev. 2013 Jan;12(1):289-309. (PMID: 22742992)
Front Neurol. 2020 Apr 17;11:288. (PMID: 32362867)
Expert Rev Neurother. 2007 Nov;7(11):1527-33. (PMID: 17997701)
J Zhejiang Univ Sci B. 2020 Sept.;21(9):673-689. (PMID: 32893525)
Neuron. 2020 Aug 5;107(3):417-435. (PMID: 32579881)
Epilepsy Behav. 2006 Mar;8(2):376-83. (PMID: 16461011)
Int J Mol Sci. 2022 Apr 24;23(9):. (PMID: 35563093)
J Adv Res. 2021 Mar 31;35:231-243. (PMID: 35024199)
Acta Neuropathol. 2015 Feb;129(2):167-82. (PMID: 25534025)
Neuropharmacology. 2010 Mar;58(3):561-8. (PMID: 19951717)
J Ethnopharmacol. 2016 Aug 2;189:361-85. (PMID: 27377337)
Neurochem Res. 2021 Jul;46(7):1627-1640. (PMID: 33710538)
J Neurosci. 2008 Mar 5;28(10):2624-32. (PMID: 18322105)
Int J Mol Sci. 2023 Oct 30;24(21):. (PMID: 37958722)
Nature. 2018 Jul;559(7715):S1. (PMID: 30046078)
Int J Mol Sci. 2017 Jun 03;18(6):. (PMID: 28587194)
J Alzheimers Dis. 2008 Oct;15(2):181-91. (PMID: 18953107)
Dialogues Clin Neurosci. 2009;11(2):111-28. (PMID: 19585947)
Transl Neurodegener. 2022 May 9;11(1):27. (PMID: 35527277)
Front Genet. 2019 Mar 01;10:153. (PMID: 30881384)
J Inflamm Res. 2023 Apr 17;16:1639-1652. (PMID: 37092127)
Ann Neurol. 2015 Apr;77(4):637-54. (PMID: 25611954)
Anal Sci. 2023 Jun;39(6):815-827. (PMID: 36840858)
FEBS Lett. 1993 Jul 5;325(3):167-72. (PMID: 7686508)
Cell Res. 2015 Jan;25(1):39-49. (PMID: 25287280)
EMBO J. 2001 Jan 15;20(1-2):27-39. (PMID: 11226152)
Clin Pharmacol Ther. 2010 Oct;88(4):475-86. (PMID: 20811351)
Cells. 2021 Mar 24;10(4):. (PMID: 33804962)
PeerJ. 2023 Apr 5;11:e15197. (PMID: 37038472)
RNA Biol. 2022 Jan;19(1):519-532. (PMID: 35442163)
Cell Res. 2012 Jan;22(1):107-26. (PMID: 21931358)
Science. 2002 Jul 19;297(5580):353-6. (PMID: 12130773)
Mol Brain. 2009 Nov 19;2:35. (PMID: 19925672)
Cell Res. 2016 Feb;26(2):217-28. (PMID: 26794868)
Mol Ther Nucleic Acids. 2022 Apr 18;28:539-557. (PMID: 35592504)
Cells. 2020 Apr 30;9(5):. (PMID: 32365809)
J Alzheimers Dis. 2021;82(s1):S51-S63. (PMID: 33523002)
FEBS Lett. 2006 Nov 13;580(26):6269-74. (PMID: 17078951)
Int J Mol Sci. 2022 Jan 04;23(1):. (PMID: 35008962)
Genes (Basel). 2023 Aug 29;14(9):. (PMID: 37761867)
Int J Mol Sci. 2018 Jul 10;19(7):. (PMID: 29996470)
Int J Mol Sci. 2023 Apr 28;24(9):. (PMID: 37175684)
JAMA Neurol. 2014 Apr;71(4):505-8. (PMID: 24493463)
Cells. 2021 Jan 29;10(2):. (PMID: 33572709)
Front Pharmacol. 2018 Feb 02;9:24. (PMID: 29456504)
Int J Mol Sci. 2022 Sep 09;23(18):. (PMID: 36142389)
Nature. 2004 Sep 16;431(7006):350-5. (PMID: 15372042)
J Cell Physiol. 2007 Feb;210(2):279-89. (PMID: 17096367)
Biosci Biotechnol Biochem. 2020 Nov;84(11):2273-2280. (PMID: 32713252)
Int J Neuropsychopharmacol. 2012 Feb;15(1):77-90. (PMID: 21329555)
Biomed J. 2018 Feb;41(1):21-33. (PMID: 29673549)
J Biol Chem. 2004 Nov 26;279(48):50078-88. (PMID: 15375165)
Nat Med. 1996 Jul;2(7):783-7. (PMID: 8673924)
Front Pharmacol. 2020 Sep 25;11:542405. (PMID: 33101016)
Chin J Nat Med. 2013 Mar;11(2):110-20. (PMID: 23787177)
Sci Rep. 2016 Jun 02;6:26834. (PMID: 27251858)
Elife. 2022 May 26;11:. (PMID: 35616532)
J Alzheimers Dis. 2012;32(2):387-96. (PMID: 22785398)

2021Y004 The Fundamental Research Funds of Zhejiang Sci-Tech University; SXAB202007 the Open Fund of Zhejiang Sci-Tech University Shaoxing Academy of Bio-medicine

Keywords: Alzheimer’s disease; GSK-3β; Gas-miR36-5p; Gastrodia elata miRNA; hyperphosphorylation of tau protein; neuroprotection

EC 2.7.11.1 (Glycogen Synthase Kinase 3 beta)
0 (MicroRNAs)
0 (Neuroprotective Agents)
0 (tau Proteins)

Date Created: 20231223 Date Completed: 20231225 Latest Revision: 20240328

20240329

PMC10744203

10.3390/ijms242417295

38139125